Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 295-301

  Buch Hansen, Trine Zeeberg ^a   Bentzen, Lise ^b   Hansen, Steinbjoern ^c   Hoeyer, Morten ^b   Jensen, Niels Viggo ^c   Saxe, Charlotte ^a   Sengeloev, Lisa ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemotherapy; Pain; Palliation; PSA response

Indexed keywords

ANTICOAGULANT AGENT; DOCETAXEL; GEMCITABINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CASTRATE REFRACTORY METASTATIC PROSTATE CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELECTROCORTICOGRAPHY; EYE THROMBOSIS; FATIGUE; HEART INFARCTION; HUMAN; INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; LUNG EDEMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; BIOASSAY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; ORCHIECTOMY; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PAIN; PALLIATIVE CARE; PREDNISONE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77953056762     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1163-x     Document Type: Article

References (24)

1. Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 5:300-318
2. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ et al (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 17:3335-3342
3. Gravis G, Bladou F, Salem N, Quart-Moulin G, Serment G, Camerlo J et al (2003) Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.Cancer 8:1627-1634
4. Morris MJ, Scher HI (2003) Clinical approaches to osseous metastases in prostate cancer. Oncologist 2:161-173
5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 6:1756-1764
6. Tannock IF, de Wit WR, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 15:1502-1512
7. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 10:1749-1753
8. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 15:1513-1520
9. Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N et al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 9:1259-1264
10. Hejna M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger WC, Marosi L et al (2000) Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 3:516-522
11. Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thurlimann B et al (2000) Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2:183-188
12. Speicher LA, Barone L, Tew KD (1992) Combined antimicrotubule ctivity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 16:4433-4440
13. Roth BJ (2005) Prostate cancer chemotherapy: emerging from the shadows. J Clin Oncol 15:3302-3303
14. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 11:3461-3467
15. Berry W, Eisenberger M (2005) Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 10:30-39
16. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA (2002) Phase II evaluation of docetaxel plus oneday oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 5:1457-1465
17. Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J et al (2005) Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 15:3352-3357
18. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA et al (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 15:2544-2549
19. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC (2006) Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 10:2143-2147
20. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ (2003) A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 12:2988-2994
21. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 1:123-128
22. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N et al (2007) Phase II study of docetaxel, estramustine phosphate, nad carpoplatin in patients with hormone-refractory prostate cancer. Eur Urol 51:1252-1258
23. Nakabayashi M, Sartor O, Jacobus S, Regan M, Taplin ME, Oh WK et al (2008) Response to docetaxel/carpoplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101:308-312
24. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Small EJ et al (2003) A phase II study of estramustine, docetaxel and carboplatin with granulocyte-colony stimulating factor support in patients with hormone refractory prostate carcinoma. Cancer and leukaemia group B 99813. Cancer 98(12):2592-2598